Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
s.l; s.l; 2024. 9 p. ilus, graf.
Não convencional em Inglês | SES-SP, HANSEN, Hanseníase, SESSP-ILSLPROD, SES-SP, SESSP-ILSLACERVO, SES-SP | ID: biblio-1556204

RESUMO

Jorge Lobo's disease (JLD) and lepromatous leprosy (LL) share several clinical, histological and immunological features, especially a deficiency in the cellular immune response. Macrophages participate in innate and adaptive inflammatory immune responses, as well as in tissue regeneration and repair. Macrophage function deficiency results in maintenance of diseases. M1 macrophages produce pro-inflammatory mediators and M2 produce anti-inflammatory cytokines. To better understand JLD and LL pathogenesis, we studied the immunophenotype profile of macrophage subtypes in 52 JLD skin lesions, in comparison with 16 LL samples, using a panmacrophage (CD68) antibody and selective immunohistochemical markers for M1 (iNOS) and M2 (CD163, CD204) responses, HAM56 (resident/fixed macrophage) and MAC 387 (recently infiltrating macrophage) antibodies. We found no differences between the groups regarding the density of the CD163, CD204, MAC387+ immunostained cells, including iNOS, considered a M1 marker. But HAM56+ cell density was higher in LL samples. By comparing the M2 and M1 immunomarkers in each disease separately, some other differences were found. Our results reinforce a higher M2 response in JLD and LL patients, depicting predominant production of anti-inflammatory cytokines, but also some distinction in degree of macrophage activation. Significant amounts of iNOS + macrophages take part in the immune milieu of both LL and JLD samples, displaying impaired microbicidal activity, like alternatively activated M2 cells


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Hanseníase Virchowiana/imunologia , Antígenos CD , Imunofenotipagem , Lobomicose/patologia , Hanseníase Virchowiana/patologia , Receptores de Superfície Celular , Óxido Nítrico Sintase Tipo II , Lobomicose/imunologia , Macrófagos
2.
J Clin Pharm Ther ; 42(5): 573-578, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28497462

RESUMO

What is known and objective Polymyxins were widely used until the 1960s; however, they fell into disfavour owing to their toxicity. The subsequent growth of infections caused by multidrug-resistant Gram-negative bacteria has led to renewed use of this class of antimicrobials in clinical practice. Acquired skin hyperpigmentation (SH) following intravenous polymyxin B treatment has been previously reported, but little is known about its pathogenesis, clinical course and treatment. To improve understanding of these issues, we conducted a prospective study of adult patients receiving intravenous polymyxin B treatment. Methods Patients receiving intravenous polymyxin B treatment were followed throughout the course of treatment. Clinical, dermatoscopic, histologic and immunohistochemical skin properties of patients who presented with SH were studied. Results and discussion Skin hyperpigmentation was noted in 8% of patients (n=20/249); however, clinical, dermatoscopic, histologic and immunohistochemical examinations were performed only in three patients for whom the consent of relatives was obtained. Histologic and immunohistochemical findings showed an abundant melanocyte-pigmented dendritic network. Langerhans cells' hyperplasia and dermal IL-6 overexpression were also found, presumably for an inflammatory process due to polymyxin B use. As polymyxin B causes the release of histamine, which is known for its melanogenic effect, it is possible that skin darkening is associated with this inflammatory mediator. What is new These clinical and dermatoscopic findings contribute to a better understanding of how the pigmentary reaction manifests following intravenous polymyxin B treatment. Conclusion We concluded that hyperpigmentation due to intravenous polymyxin B treatment is associated with an inflammatory process and subsequent melanocyte activation. Although the pigmentary disorder neither influences the outcome of the therapy nor warrants discontinuation of treatment, it nevertheless considerably affects the patient's quality of life.


Assuntos
Antibacterianos/efeitos adversos , Hiperpigmentação/induzido quimicamente , Melanócitos/metabolismo , Polimixina B/efeitos adversos , Administração Intravenosa , Adulto , Antibacterianos/administração & dosagem , Farmacorresistência Bacteriana Múltipla , Feminino , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Humanos , Inflamação/induzido quimicamente , Inflamação/patologia , Masculino , Pessoa de Meia-Idade , Polimixina B/administração & dosagem , Estudos Prospectivos , Qualidade de Vida
3.
Braz. j. med. biol. res ; 45(7): 644-651, July 2012. ilus, tab
Artigo em Inglês | LILACS | ID: lil-639457

RESUMO

Infection with Bartonella spp may cause cardiac arrhythmias, myocarditis and endocarditis in humans. The aim of the present study was to evaluate a possible association between Bartonella spp bacteremia and endocarditis, arrhythmia and Chagas cardiomyopathy in patients from Brazil and Argentina. We screened for the presence of bacterial 16S rRNA in human blood by PCR using oligonucleotides to amplify a 185-bp bacterial DNA fragment. Blood samples were taken from four groups of subjects in Brazil and Argentina: i) control patients without clinical disease, ii) patients with negative blood-culture endocarditis, iii) patients with arrhythmias, and iv) patients with chronic Chagas cardiomyopathy. PCR products were analyzed on 1.5% agarose gel to visualize the 185-bp fragment and then sequenced to confirm the identity of DNA. Sixty of 148 patients (40.5%) with cardiac disease and 1 of 56 subjects (1.8%) from the control group presented positive PCR amplification for Bartonella spp, suggesting a positive association of the bacteria with these diseases. Separate analysis of the four groups showed that the risk of a Brazilian patient with endocarditis being infected with Bartonella was 22 times higher than in the controls. In arrhythmic patients, the prevalence of infection was 45 times higher when compared to the same controls and 40 times higher for patients with Chagas cardiomyopathy. To the best of our knowledge this is the first report of the association between Bartonella spp bacteremia and Chagas disease. The present data may be useful for epidemiological and prevention studies in Brazil and Argentina.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Arritmias Cardíacas/microbiologia , Bacteriemia/microbiologia , Infecções por Bartonella/complicações , Cardiomiopatia Chagásica/complicações , Endocardite Bacteriana/microbiologia , Argentina , Brasil , Estudos de Casos e Controles , DNA Bacteriano/análise
4.
Braz J Med Biol Res ; 45(7): 644-51, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22584639

RESUMO

Infection with Bartonella spp may cause cardiac arrhythmias, myocarditis and endocarditis in humans. The aim of the present study was to evaluate a possible association between Bartonella spp bacteremia and endocarditis, arrhythmia and Chagas cardiomyopathy in patients from Brazil and Argentina. We screened for the presence of bacterial 16S rRNA in human blood by PCR using oligonucleotides to amplify a 185-bp bacterial DNA fragment. Blood samples were taken from four groups of subjects in Brazil and Argentina: i) control patients without clinical disease, ii) patients with negative blood-culture endocarditis, iii) patients with arrhythmias, and iv) patients with chronic Chagas cardiomyopathy. PCR products were analyzed on 1.5% agarose gel to visualize the 185-bp fragment and then sequenced to confirm the identity of DNA. Sixty of 148 patients (40.5%) with cardiac disease and 1 of 56 subjects (1.8%) from the control group presented positive PCR amplification for Bartonella spp, suggesting a positive association of the bacteria with these diseases. Separate analysis of the four groups showed that the risk of a Brazilian patient with endocarditis being infected with Bartonella was 22 times higher than in the controls. In arrhythmic patients, the prevalence of infection was 45 times higher when compared to the same controls and 40 times higher for patients with Chagas cardiomyopathy. To the best of our knowledge this is the first report of the association between Bartonella spp bacteremia and Chagas disease. The present data may be useful for epidemiological and prevention studies in Brazil and Argentina.


Assuntos
Arritmias Cardíacas/microbiologia , Bacteriemia/microbiologia , Infecções por Bartonella/complicações , Cardiomiopatia Chagásica/complicações , Endocardite Bacteriana/microbiologia , Adulto , Idoso , Argentina , Brasil , Estudos de Casos e Controles , DNA Bacteriano/análise , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
7.
Transfus Med ; 18(5): 287-91, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18937735

RESUMO

Bartonella henselae is the agent of cat scratch disease and bacillary angiomatosis. Blood donors can be asymptomatic carriers of B. henselae and the risk for transmission by transfusion should be considered. The objective of this study was to demonstrate that B. henselae remains viable in red blood cell (RBC) units at the end of the storage period. Two RBC units were split into two portions. One portion was inoculated with B. henselae and the other was used as a control. All units were stored at 4 degrees C for 35 days. Aliquots were collected on a weekly basis for culture in a dish with chocolate agar, ideal for the cultivation of this agent. Samples were collected on days 1 and 35 and taken for culture in Bact/Alert R blood culture bottles. Aliquots taken simultaneously were fixed in Karnovsky's medium for subsequent electron microscopy evaluation. Samples from infected bags successfully isolated B. henselae by chocolate agar culture, although Bact/Alert R blood culture bottles remained negative. Bartonella spp. structures within erythrocytes were confirmed by electron microscopy. The viability of B. henselae was demonstrated after a storage period of RBC units. These data reinforce the possibility of infection by transfusion of blood units collected from asymptomatic blood donors.


Assuntos
Angiomatose Bacilar/transmissão , Bartonella henselae/fisiologia , Preservação de Sangue , Sangue/microbiologia , Transfusão de Eritrócitos/efeitos adversos , Eritrócitos/microbiologia , Angiomatose Bacilar/prevenção & controle , Bartonella henselae/isolamento & purificação , Portador Sadio/microbiologia , Temperatura Baixa , Criopreservação , Humanos , Transfusão de Plaquetas/efeitos adversos , Fatores de Tempo
9.
Braz J Infect Dis ; 11(3): 383-4, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17684645

RESUMO

We reported one case of human immunodeficiency virus and hepatitis C virus co-infected patient who presented a significant improvement of human papillomavirus (HPV) lesions during the treatment of chronic hepatitis using peg-interferon alfa-2b and ribavirin.


Assuntos
Antivirais/uso terapêutico , Interferon-alfa/uso terapêutico , Infecções por Papillomavirus/tratamento farmacológico , Ribavirina/uso terapêutico , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Quimioterapia Combinada , Hepatite C/tratamento farmacológico , Humanos , Interferon alfa-2 , Masculino , Polietilenoglicóis , Proteínas Recombinantes , Resultado do Tratamento
10.
Braz. j. infect. dis ; 11(3): 383-384, June 2007. ilus
Artigo em Inglês | LILACS | ID: lil-457643

RESUMO

We reported one case of human immunodeficiency virus and hepatitis C virus co-infected patient who presented a significant improvement of human papillomavirus (HPV) lesions during the treatment of chronic hepatitis using peg-interferon alfa-2b and ribavirin.


Assuntos
Humanos , Masculino , Antivirais/uso terapêutico , Interferon-alfa , Infecções por Papillomavirus/tratamento farmacológico , Ribavirina/uso terapêutico , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Quimioterapia Combinada , Hepatite C/tratamento farmacológico , Resultado do Tratamento
11.
Braz. j. infect. dis ; 2(6): 300-303, Dec. 1998. tab
Artigo em Inglês | LILACS | ID: lil-314775

RESUMO

Baccilary angiomatosis has recently been described as a disease that can spread systematically and that is potentially fatal. It is caused by Bartonella henselae and B. quintana, and presents as especially pronounced signs and symptoms in patients suffering from acquired immunodeficiency syndrome (AIDS). To clarify the pathogenesis of the disease and to try to define the relationships among baccilary angiomatosis, cat scratch disease and Carrión's bartonellosis, the authors of this study have attempted to develop an experimental model using mice that were immunocompetent as well as those that had their cellular immunity genetically compromised. A know concentration of B. henselae was inoculated intradermally in Balb/c an isogenic mice or an athymic group of the same lineage. Blood samples were taken on days-0, 3, 7, 10, 14, 28, and 60 after inoculation for indirect immunofluorescence antibody testing. On the 21st and 60th day, one animal from each group was sacrificed and a post mortem carried out including histological evaluation of the liver, spleen, lymph nodes, skin and other organs. Hemocultures of the sacrificed animals were collected. All results of serologic response, cultures and histologic examination were negative. The authors discuss the methodology, especially the use of isogenic animals of the same lineage in B. henselae infection, with and without immunodeficiency, and the resources for the negative results of histopathology, serology and cultures.


Assuntos
Camundongos , Angiomatose Bacilar , Bartonella henselae , Bartonella quintana , Doença da Arranhadura de Gato/etiologia , Síndrome da Imunodeficiência Adquirida/complicações , Camundongos Endogâmicos BALB C/imunologia , Modelos Animais de Doenças , Infecções por Bartonella/etiologia , Ratos Nus
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA